The addition of complementary DNA (cDNA) microarray technology allowed for an extended BC classification, able to define four groups with different prognosis and molecular targets, namely: luminal-A, luminal-B, HER2-enriched and basal-like. Here, ERBB2 is linked to breast cancer.